What the research found
The FDA's Digital Health Center of Excellence issued a discussion paper acknowledging that generative-AI-enabled devices may introduce risks unlike those of traditional software or earlier AI devices, and opened docket FDA-2026-N-7874 for comment until 19 October 2026. It sketches a two-axis risk framework, a premarket approach built on 'competency assessment' (non-clinical benchmarking plus clinical confirmation, inspired by how physicians are trained and examined) and several options for risk-proportionate postmarket monitoring, including for foundation models and agentic systems. CDRH director Michelle Tarver framed it as a transparent process intended to serve as a potential model for regulators elsewhere.
Generative AI is already in clinical settings while the framework for judging it is still being drafted in public, which is both the clearest statement yet that clearance is not proof, and an open door for providers to say what evidence they'd actually need.